Coronary Heart Disease Diagnostic Imaging Devices Market: as photon-counting CT and AI-powered plaque analysis converge into a single imaging-to-treatment-planning workflow, coronary CT angiography is displacing invasive catheterization for an expanding share of chest pain evaluations, so payer coverage decisions for AI plaque analysis are compounding demand on top of the underlying hardware upgrade cycle.

The global coronary heart disease diagnostic imaging devices market size was USD 5.84 Billion in 2025 and is expected to register a revenue CAGR of 6.8% during the forecast period.Market revenue growth is driven by factors such as the convergence of photon-counting CT hardware with AI-powered coronary plaque analysis software, the sustained and substantial burden of coronary heart disease, and expanding payer coverage for AI-assisted plaque analysis.The first driving factor is the convergence of photon-counting CT hardware with AI-powered plaque analysis software into a single imaging-to-treatment-planning workflow.Siemens Healthineers launched its NAEOTOM Alpha photon-counting CT platform in February 2024, with published studies showing the platform can more than halve referrals for invasive coronary angiography when used for CCTA evaluation.The second driving factor is the sustained and substantial burden of coronary heart disease documented by national health authorities.The CDC confirmed in its September 2025 provisional mortality report that heart disease caused 683,037 deaths in the United States in 2024, remaining the leading cause of death, with approximately 20.5 million American adults living with coronary artery disease.The third driving factor is expanding commercial payer coverage for AI-assisted coronary plaque analysis, which converts a hardware capability into a reimbursable clinical service.Heartflow, the AI-powered coronary plaque analysis company, reported third-quarter 2025 revenue of USD 46.3 Million, a 41% year-over-year increase, following its August 2025 initial public offering.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single AI-powered plaque analysis platform widens its addressable revenue every time a new commercial payer adds coverage, without the vendor having to sell a new hardware unit to generate that incremental revenue.Once a photon-counting or dual-source CT installed base exists at a hospital, adding AI plaque analysis software to the same scanner captures incremental per-scan revenue without a new capital equipment sale, so software revenue compounds on top of the hardware upgrade cycle as payer coverage expands the reimbursable patient population.As a result, demand and revenue share are concentrating around platforms that combine the broadest hardware installed base with the most extensively payer-covered AI software layer, that hold both photon-counting resolution and reimbursed plaque analysis, and the forecast tilts toward these integrated platforms rather than hardware-only or software-only point solutions.For instance, on October 1, 2025, UnitedHealthcare and Cigna began commercial coverage of Heartflow Plaque Analysis, converting a previously self-pay or limited-coverage AI service into a broadly reimbursed clinical workflow step for CCTA-based coronary artery disease evaluation across those payers' covered populations.These are some of the key factors driving revenue growth of the market.

Because published workforce analysis indicates that annual training output of qualified imaging specialists in several markets is sufficient only to maintain existing numbers, skilled professional emigration to higher-compensation markets creates a persistent specialist capacity constraint relative to growing imaging study volume.

Reimbursement variability is a second constraint, because CCTA and advanced cardiac imaging reimbursement policy varies substantially across payer systems and geographic markets, creating commercial uncertainty for hospitals evaluating capital investment in next-generation photon-counting CT systems.

High capital cost is a third constraint, since dual-source and photon-counting CT platforms constrain advanced cardiac imaging technology adoption to larger hospital systems and dedicated cardiac imaging centres, leaving community hospitals dependent on conventional single-source CT or referral relationships.

These factors substantially limit coronary heart disease diagnostic imaging devices market growth over the forecast period.

The clearest driver of demand is the integration of photon-counting CT hardware with AI-powered coronary plaque analysis software into a single diagnostic-to-treatment-planning workflow. A CT platform only changes the standard of care if its image quality is good enough to replace, not just supplement, invasive angiography, and Siemens Healthineers' NAEOTOM Alpha has cleared that bar with published data showing it can more than halve referrals for invasive coronary angiography. At RSNA 2025 in Chicago, Siemens Healthineers launched Syngo.CT Coronary Cockpit, AI-powered software that integrates with its dual-source and photon-counting CT scanners to provide automated segmentation, labelling, and visualisation of coronary plaques before percutaneous coronary intervention. GE HealthCare received FDA 510(k) clearance for its Photonova Spectra photon-counting CT system, and Philips introduced its Verida spectral CT system at RSNA 2025, with US availability slated for 2026, confirming that photon-counting and spectral CT are becoming standard next-generation platforms across all three major imaging vendors. The effect on the market is that CCTA is becoming the centrepiece of coronary artery disease evaluation for a growing share of patients, reducing invasive catheterisation referrals and shifting capital investment toward integrated CT-plus-AI platforms. These are some of the key factors driving revenue growth of the market.

The second driver is the extension of commercial payer coverage to AI-powered coronary plaque analysis software. An AI diagnostic software service only scales past early adopter hospitals once major payers agree to reimburse it, and Heartflow's Plaque Analysis crossed that threshold when UnitedHealthcare and Cigna began coverage on October 1, 2025, so the same installed base of CT scanners can now generate reimbursed AI software revenue that did not previously exist. Heartflow reported third-quarter 2025 total revenue of USD 46.3 Million, a 41% year-over-year increase, with gross margin of 76.5%, and completed its initial public offering in August 2025, raising approximately USD 364.2 Million. The company's DECIDE real-world prospective registry showed Heartflow Plaque Analysis drove medical management changes in over half of patients beyond CCTA alone, providing the clinical evidence base that supported the payer coverage decisions. The effect on the market is that AI plaque analysis software revenue is now growing independently of, and faster than, the underlying CT hardware replacement cycle, as payer coverage expansion broadens the reimbursed patient population. These are some of the key factors driving revenue growth of the market.

“UnitedHealthcare and Cigna began covering Heartflow Plaque Analysis on October 1, 2025, converting an AI diagnostic service that had previously depended on self-pay or limited coverage into a broadly reimbursed clinical workflow step.”

However, the coronary heart disease diagnostic imaging devices market faces severe adoption constraints from radiologist workforce shortages, reimbursement variability, and the high capital cost of advanced CT platforms.

Because published workforce analysis confirms that in several markets annual training output of qualified imaging specialists is sufficient only to maintain existing numbers, skilled professional emigration to higher-compensation healthcare systems creates a persistent specialist capacity constraint relative to growing imaging study volume.

Reimbursement policy variability is a second constraint, since CCTA and advanced cardiac imaging reimbursement differs substantially across payer systems and geographic markets, and industry analysis confirms that reimbursement changes are expected to materially drive the pace of CCTA and plaque analysis implementation.

High capital cost is the third constraint, because dual-source and photon-counting CT platforms including Siemens Healthineers' NAEOTOM Alpha and comparable systems from GE HealthCare and Canon Medical Systems constrain advanced cardiac imaging technology adoption to larger hospital systems with sufficient capital budgets.

These factors substantially limit coronary heart disease diagnostic imaging devices market growth over the forecast period.

Based on technology, the global coronary heart disease diagnostic imaging devices market is segmented into dual-source and photon-counting CT, AI-assisted plaque analysis software, and conventional single-source CT. Dual-source and photon-counting CT technology, exemplified by Siemens Healthineers' NAEOTOM Alpha and GE HealthCare's newly FDA-cleared Photonova Spectra, delivers ultra-high resolution and lower radiation doses by combining photon-counting detection with dual-source acquisition architecture. The AI-assisted plaque analysis software segment, anchored by Siemens Healthineers' Syngo.CT Coronary Cockpit and Heartflow's Plaque Analysis platform, is expected to register the most rapid revenue growth rate over the forecast period, driven by expanding commercial payer coverage.

Based on regional analysis, the coronary heart disease diagnostic imaging devices market in North America accounted for the largest revenue share in 2025. The United States drives the regional position through the CDC-confirmed burden of approximately 20.5 million adults living with coronary artery disease and 683,037 heart disease deaths recorded in 2024, combined with the concentrated presence of GE HealthCare's Chicago headquarters. GE HealthCare confirmed FY2024 Imaging segment organic revenue growth of 8% to USD 9.074 Billion, and Heartflow's Nasdaq listing and expanding UnitedHealthcare and Cigna payer coverage further anchor North America as the centre of AI plaque analysis commercialisation. The concentration of FDA clearances for photon-counting CT platforms in the United States also means new imaging technology is often launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate in the global coronary heart disease diagnostic imaging devices market over the forecast period.

Germany, France, and the United Kingdom represent significant national coronary heart disease diagnostic imaging markets within Europe, anchored by Siemens Healthineers' Erlangen, Germany headquarters and the company's leading European installed base of dual-source and photon-counting CT systems. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have raised costs for specialty detector components and contrast agent supply chains for European cardiac CT manufacturers, a disruption that has run through 2026 and contributes to European imaging equipment pricing pressure.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global coronary heart disease diagnostic imaging devices market over the forecast period.

Japan, China, and India represent the three largest national coronary heart disease diagnostic imaging markets within the region, anchored by Canon Medical Systems' continued cardiac CT research and development investment in Japan. Rising coronary artery disease incidence and improving cardiac catheterisation laboratory infrastructure across urban China and India are expanding the addressable installed base for advanced CT and nuclear medicine systems, leaving more structural room for growth than in the already-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate in the global coronary heart disease diagnostic imaging devices market over the forecast period.

Brazil and Mexico represent the two largest national coronary heart disease diagnostic imaging markets within the region, with access to advanced CT and nuclear medicine imaging concentrated at private and academic hospital networks. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have maintained elevated import costs for imaging equipment components entering Brazilian and Mexican distribution networks, a disruption that has run through 2026 and slows procurement beyond the largest private hospital networks in the region.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global coronary heart disease diagnostic imaging devices market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for advanced cardiac imaging infrastructure, supported by the Vision 2030 healthcare investment programme, while the wider Gulf and North African sub-regions are still building the basic CT and nuclear medicine infrastructure advanced coronary imaging requires from scratch.